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Abstract

PREVENTATIVE AND THERAPEUTIC EFFECTS OF BMSC EXOSOME ON
PERIODONTAL DISEASE

By Jin Ha Kim, BSc

A thesis submitted in partial fulfillment of the requirements for the degree of Master of
Science in Physiology and Biophysics at Virginia Commonwealth University

Virginia Commonwealth University, 2020

Mentor: Zhao Lin, BDS, MS, MMSc, PhD
Associate Professor, Department of Periodontics

Periodontitis is an inflammatory disease caused by the imbalance between host
immune response and bacterial infection. Strategies to manage the uncontrolled,
excessive immune response and to promote tissue healing are in great demand.
Therapies based on mesenchymal stem cells (MSCs) are promising and the clinical
effects of MSCs are largely mediated by their secretome, especially exosomes.
Previously, we isolated and purified exosomes secreted by human bone marrow
mesenchymal stem cells (hBMSC). These exosomes have proliferative, chemotactic,
anti-inflammatory and anti-osteoclastic function in vitro. In this study, we had two
hypotheses: 1) hBMSC exosomes would prevent periodontal inflammation and alveolar
bone loss with immunomodulatory function; 2) hBMSC exosomes would enhance
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periodontal tissue regeneration. To test these hypotheses, we used a rodent ligatureinduced experimental periodontitis model. In the preventative experiment, rats were
treated with hBMSC exosomes concurrently with ligature placement. In the regenerative
experiment, rats were treated with hBMSC exosomes for 3 weeks and 6 weeks after the
experimental periodontitis was induced. Our results show that, in the preventive study,
hBMSC exosome treatment led to less disease progression as evidenced by increased
alveolar bone volume, decreased linear bone loss, and less lymphocyte infiltration in the
subepithelial area. However, through micro-CT and gene expression analyses, no
significant differences were seen between the exosome treatment and control in the
regenerative study at both time points. In summary, hBMSC exosomes can ameliorate
the development of periodontitis via an immunomodulatory effect. However, more
studies are needed in the future to investigate their regenerative potential in periodontal
tissues.
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CHAPTER 1: INTRODUCTION

1.1.

PERIODONTAL DISEASE
Periodontal disease is one of the most prevalent inflammatory diseases (1).

Periodontal disease refers to the inflammatory process in response to the overgrowth of
dental plaque caused by dysbiosis of bacteria complex, which often results in alveolar
bone loss, tooth mobility and finally loss of the affected tooth (2). According to Centers
for Disease Control and Prevention (CDC), one out of every two American adults aged
30 and over has periodontal disease (3). Progression of periodontal disease can be
unrecognized for a long time due to its slow and painless nature. Disease progression
may have begun at younger age, but people often are first aware of the periodontal
disease at older age when the irreversible damage has already been done. The
prevalence of periodontal disease increases with age (4, 5). With more people living
longer, the number of people developing periodontal disease will increase even more
(6). In addition to increased prevalence in older age and detrimental effects on
periodontal tissue, chronic periodontitis is associated with other systemic disease such
as atherosclerosis, pneumonia, rheumatoid arthritis, adverse pregnancy outcome,
diabetes and cancer (7-15). Periodontitis can also have a significant effect on the
psychosocial well‐being, as the disease causes the discomfort, food intake difficulty and
changes in facial appearance. With physical impairment and psychological distress,
periodontitis has a negative impact on life quality.

3

1.2

PATHOGENESIS OF PERIODONTAL DISEASE
Host immune response plays a central role in the periodontal disease

pathogenesis. In healthy condition, periodontal tissues are able to manage the bacterial
infection with the controlled host immune response. When the balance between the
control mechanism and bacterial infection is lost, disease progresses and it leads to the
periodontal tissue damage.

Bacteria colonize plaque biofilms on the tooth surface and initiate inflammatory
responses (16). Firm attachment of the plaque on the tooth surface makes it impossible
for the host immune system to remove pathogens and continue to insult the periodontal
tissues (17). Junctional epithelium is the first periodontal structure to encounter bacterial
pathogens which can further cross the junctional epithelium and penetrate into the
underlying connective tissue (18). Resident cells detect the molecular pattern
associated with pathogens (PAMPs) such as lipopolysaccharide (LPS) and Toll-like
receptors on the cells bind with PAMP causing the activation of proinflammatory
transcription factors, such as NFκB and AP-1 (19, 20), and the subsequent synthesize
and release of inflammatory cytokines. Once the inflammation has been initiated,
marginal periodontal ligament fibers are destroyed as a result of increased proteinase
production and activity in the host immune system and therefore periodontal pockets
are formed. Bacterial plaques spread apically along the root surface and deepen the
pocket. The junctional epithelial cells are stimulated to proliferate and apically migrate
along the root (21).
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Gingival blood vessels below the junctional epithelium become inflamed.
Neutrophils exit the post-capillary venules and migrate into the gingival sulcus (22).
Neutrophils can recruit T-helper 17 cells (Th17) to the infection site and more
proinflammatory cytokines are produced. In addition, they promote the accumulation of
B cells and plasma cells which express RANKL, a key osteoclastogenic cytokine, to
induce bone resorption (23).

Macrophages polarize into two distinct phenotypes, M1 and M2. M1
macrophages are induced by the LPS of microorganism or by the Th1 related cytokines
like IFN-γ, and secrete inflammatory cytokines such as TNF-α, IL-1β, IL-6 (24). M1
macrophages can phagocytize microorganisms and promote inflammatory response,
which contributes to the degradation of the collagen matrix in connective tissue (25). M2
macrophages are induced by the stimulation of Th2 related cytokines such as IL-4 and
IL-13. They inhibit the inflammatory process by the secretion of anti-inflammatory
cytokines including IL-10. Also, they can secrete TGF-β to promote cell proliferation and
tissue regeneration (26). M1 rather than M2 macrophages predominate in the
progression of chronic periodontitis (27).

Lymphocytes are activated by two types of signals and invade into periodontal
tissue: one is the activation of antigen receptor of lymphocytes themselves and the
other is the antigen-presenting cells, APC. Activated lymphocytes are the main source
of RANKL, which induces osteoclastogenesis (28). RANKL/OPG/RANK system
manages the balance of alveolar bone metabolism (29). RANKL binds to the receptor
RANK on the surface of osteoclast or osteoclast precursor. The binding triggers
5

Figure 1: Immune response during periodontal disease (description in the text).
Source: (Muñoz-Carrillo et al., 2019)

osteoclasts to accumulate on the bone surface. OPG inhibits the biological functions of
RANKL as a decoy ligand for RANK (30). Th1 lymphocytes also secrete inflammatory
cytokines such as TNF-α and IL-1β, which cooperates with Th17 lymphocytes in
producing RANKL. Overall, lymphocytes have an important role in the progression of
periodontitis and bone resorption (31, 32).

1.3

CURRENT TREATMENTS FOR PERIODONTAL DISEASE
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Current treatments of periodontal disease are divided into non-surgical
treatment and surgical treatment. Traditional treatments focus on the mechanical
debridement procedures such as scaling and root planing and allow the periodontal
tissue to restore itself (33). Complete elimination of bacterial biofilm with mechanical
debridement procedures is usually unachievable because of the difficulty in accessing
deep and tortuous pockets (34). Bacteria would recolonize within a week and infection
will continue to thrive (35). Systemic antibiotics can be used along with the mechanical
procedures in certain patients to improve the treatment efficacy. However, systemic
antibiotics should be used with caution as unnecessary use can develop antibiotic
resistance (36).

Periodontal surgical treatments focus on the elimination of periodontal pockets
and the regeneration of periodontal apparatus. Pocket reduction surgery is a
conservative procedure which reduces the soft tissue of periodontal pockets and
creates new epithelial attachment with open access and debridement (37). The
regeneration of periodontium can be accomplished with surgical treatments such as
guided tissue regeneration and bone grafting. Although restoration to the original
periodontal condition is not often achieved (38), periodontal surgical treatments can still
be beneficial to people with severe periodontitis. In effort to overcome the limitations of
current treatments, such as unpredictable outcome, sophisticated and complex
procedures and high cost, researchers are searching for new therapies for periodontal
regeneration.

1.4

REGENERATION POTENTIAL OF MESENCHYMAL STEM CELLS
7

Adult mesenchymal stem cells (MSCs) are capable of multilineage differentiation
and self-renewal (39, 40). Bone marrow is the most common source for MSCs while
they exist in almost all tissues. Human bone marrow stem cells (hBMSCs) have been
widely used for tissue regeneration and cell-based therapies because of their
therapeutic effects. MSCs have the ability to migrate to the inflammation site and the
potential to differentiate into various cell types. Once activated, they can secrete antiinflammatory molecules to suppress excessive inflammation and have
immunomodulatory functions (41).

Past research has reported up to 20% of cementum and alveolar bone
regeneration after MSC treatment in experimental defects in dogs (42). Also, positive
clinical results were obtained in a small clinical trial (43). The amount of MSCs in the
bone marrow is very low (44) while a large number of cells are required for clinical
applications. Expansion in vitro is essential to obtain the adequate amount of cells.
However, long-term culture and higher passages can lead to cell transformation and
decrease in differentiation ability (45-47). While MSCs appear to have high regeneration
potential, many challenges remain for their clinical application (48).

1.5

MSC DERIVED EXOSOMES
Exosomes are specific extracellular vesicles (EVs) secreted into extracellular

fluid by all cells acting as messengers to communicate with other cells. Exosomes are
nanoscale lipid bilayer EVs that carry lipids, mRNA, miRNA and proteins derived from
the parental cell (49, 50). EVs are classified into three subtypes: exosomes,
microvesicles (MVs), and apoptotic bodies (51, 52). Biogenesis process of exosomes
8

Figure 2: Endocytosis vesicle is formed from the plasma membrane which develops
into late endosome. MVB is formed with inward budding in the cytosol from the
endosome. Intraluminal vesicles in the MVB are released into extracellular space
called exosomes. Source: (Schorey et al., 2015)

consists of four phases: initiation, endocytosis, multivesicular body (MVB) development,
and release (53). Endosome is formed with endocytosis from the plasma membrane.
Inward budding of endosome leads to the formation and accumulation of intraluminal
vesicles inside the lumen developing MVB. MVB merges with the plasma membrane to
release intraluminal vesicles into the extracellular space, which are called the exosomes
(54).
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Figure 3: Exosomes are nanoscale extracellular vesicles containing specific
proteins, RNAs and lipids. Proteins include HSP70, 90, GAPDH. Proteins involved in
synthesis (Alix, ESCRT proteins, TGS101), and membrane associated or
transmembrane proteins (RAB, Annexins, CAMs, Integrins, Tetraspanins, MHC I and
II) and other cytosolic proteins. Source: (Cooper et al., 2020)

Exosomes contain plasma, cytosolic and nuclear proteins (55). Alix and TSG101
proteins are associated with exosome biogenesis, and RAB proteins, Annexins,
integrins, major histocompatibility complex (MHC), tetraspanins are associated with
membrane function (56). Tetraspanins such as CD9, CD81, CD82 and CD63 are
involved in cellular interactions through binding with integrins and MHC (57). HSP70
and HSP90 are common cargo proteins (58). The associated pathway analysis of
exosomal proteins revealed Integrin and mTOR signaling pathways, both of which are
essential in osteoblast differentiation and bone formation (59).
10

Another abundant component of exosome cargo is miRNAs which regulate gene
expression. miRNAs in exosomes represent the parental cell type and condition (50).
Therefore, it is possible to therapeutically alter cell function through directing engineered
miRNAs into exosomes (60, 61). Many studies proved that exosomes serve to convey
signals from cell to cell (62-64). The transportation of miRNAs from parental cell to
target cell results in the miRNA-mediated alteration in gene expression and cellular
function. Thereby this is an important paracrine signaling mechanism (65), which can be
used in the regenerative therapy. For example, exosomes have been reported to protect
against acute kidney injury by altering cellular activities in epithelial/mesenchymal
transition, matrix remodeling, apoptosis, differentiation, inflammation and repair process
(66).

There are several advantages of using MSC exosomes in regenerative medicine
instead of MSC as a whole cell. The small size of exosomes allows them to circulate
throughout the body whereas MSCs are too large to pass beyond the capillary bed. A
cell-derived lipoprotein coat of exosomes protects their cargo from degradation in the
systemic circulation (49). Exosome delivery can avoid the transfer of mutated or
damaged cells which might exhibit oncogenic potential and other noxious effects.
Moreover, the use of exosomes can overcome the scarcity of MSCs because exosomes
can be harvested multiple times from MSC culture (67). While more research is needed,
it is certain that MSC exosomes are promising agents as stem cell-based, cell free
regenerative therapy.
1.6

MSC DERIVED EXOSOMES IN BONE REGENERATION
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MSC exosome-mediated regeneration has received great attention in the past
decade. For instance, exosomes reduced the morphologic and functional damage of
glycerol-induced acute kidney injury in SCID mice by inducing proliferation of tubular
cells (68). BMSC-derived exosomes preserved retinal ganglion cell function and
promoted axon regeneration through miRNA-dependent mechanisms (69). Treatment of
MSC exosomes improved cardiac epicardial remodeling and increased left ventricular
ejection fraction (70). The progression of hypoxic-induced pulmonary hypertension was
significantly inhibited by intravenous MSC exosome injection (71).
In regard to bone regeneration, some studies demonstrated MSC exosomes
have the ability to activate osteogenic differentiation, stimulate angiogenesis, and
promote bone formation (72-75). miRNAs in hBMSC exosomes such as let-7a are a
regulator of osteoblast differentiation (76). Many studies demonstrated hBMSC-derived
exosomes carry miRNAs that contributes to bone regeneration (77-78). In addition to
miRNAs, there are other important proteins mediating essential signaling pathways in
bone regeneration. For example, the secretion factors from MSCs, including exosomes,
can stimulate the expression of RUNX2, a transcription factor that regulates
osteogenesis by promoting the differentiation of pluripotent stem cells into osteoblasts
(79). hBMSC exosomes activates multiple signaling pathways such as Akt, Erk1/2 and
STAT3 to induce angiogenic responses in fibroblasts (80). Wnt pathway plays important
role in bone repair. hBMSC exosomes activates the Wnt3a-β-catenin pathway and
induces angiogenic capacity of fibroblast (81). hBMSC exosomes also express high
level of BMP9, transforming growth factor β1 (TGFβ1), and vascular endothelial growth
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factor (VEGF), and platelet-derived growth factor (PDGF) (82), all of which are
important growth factors in osteogenic differentiation and angiogenesis (83-85).
Previous work in our lab demonstrated the effects of hBMSC exosomes on cell
proliferation, migration, and cytokine production in vitro. The intensity of hMSC
migration and proliferation increased as the exosomes dosage increased. From protein
arrays, various cytokines and growth factors were enriched in the exosomes compare to
the supernatant of the culture medium. The exosomes also showed anti-inflammatory
effect, which suppressed IL-6 production in macrophage-like cells, and inhibited
osteoclast differentiation in vitro. Many small RNAs, such as miR-486, 760, 6087, 7641,
and 4792, are highly enriched in exosomes compared to total cell lysate.
1.7

SUMMARY
The host inflammatory response triggered by oral microbial biofilm on tooth

surface causes periodontitis. Complications such as association with systemic disease,
physical discomfort and negative psychosocial impact due to periodontal deformity can
remarkably reduce the quality of life of patients. With the limitations of current
treatments and the expected increase of disease prevalence, new innovative treatment
which targets the uncontrolled periodontal inflammation is highly desired. While MSC is
widely recognized, the applications of MSC in regenerative medicine have experienced
several challenges. Exosomes secreted from MSCs have the advantages to overcome
the limitations of whole cell delivery while retaining the beneficial regeneration potential
of MSCs. MSC exosomes may serve as a novel stem cell-based, cell free regenerative
therapy for treating periodontitis.
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CHAPTER 2: SPECIFIC AIMS

Progressive periodontal inflammation leads to the destruction of periodontal
tissues including alveolar bone. Recent studies demonstrated the outcome of stem cell
exosome therapy in bone regeneration. However, the impact of MSC exosomes in the
periodontal diseases is still not clear. The overall objective of this study is to explore the
preventative and therapeutic potential of hBMSC exosomes therapy for periodontitis.
The first hypothesis was that hBMSC exosomes could prevent periodontal inflammation
and alveolar bone loss. The second hypothesis was that hBMSC exosomes may
promote periodontal regeneration after the disease was established.

2.1 Specific Aims

The following aims were developed to test our main hypothesis:

Specific Aim 1: To determine if hBMSC exosomes would prevent
periodontal inflammation and alveolar bone loss in ligation-induced periodontitis.

Sub-aim 1: To determine the effect of hBMSC exosomes on alveolar bone
loss via Micro-CT analysis. Periodontitis was induced at rat maxillary molars by suture
ligation and, concurrently, hBMSC exosomes were injected to gingival papillae every
week. 3 weeks later, the left and right maxillae of the subjects were harvested, and
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subsequently analyzed with the standardized micro-CT protocol. Bone volume and
alveolar bone level were both quantified.

Sub-aim 2: To perform a histological analysis of periodontal tissue from
the preventative model. Samples from the harvested maxillae were demineralized and
sectioned. The slides were then stained with H&E to investigate the morphology and to
qualitatively show the extent of prevention in disease progression.

Sub-aim 3: To perform a histomorphometric analysis of infiltrated
lymphocytes in gingival subepithelial tissue to determine the effect of exosome on
periodontal inflammation. Images of gingival tissue from H&E stained sections were
captured. Lymphocytes in the gingival subepithelial tissue were quantified by specific
characteristics of lymphocyte.

Specific Aim 2: To determine if hBMSC exosomes would promote
periodontal regeneration in ligation-induced periodontitis.

Sub-aim 1: To perform Micro-CT analysis of bone volume and alveolar
bone level to determine the effect of hBMSC exosomes on periodontal bone
regeneration. Periodontitis was induced at rat maxillary molars by suture ligating for 3
weeks. After that, the sutures were removed and weekly exosome injection was started
for 3 or 6 weeks. The left and right maxillae were harvested, and subsequently analyzed
with the standardized micro-CT protocol. Bone volume and alveolar bone level were
both quantified.
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Sub-aim 2: To determine the gene expression profiles of periodontal
tissues during inflammation resolution and tissue regeneration. Gingival papillae were
dissected from formalin-fixed maxillary samples and RNA was extracted. RT-qPCR was
performed to analyze the expression of a panel of genes related to inflammation
activation and resolution.

2.2 SIGNIFICANCE OF THE STUDY

The purpose of these studies was to establish the therapeutic effects of hBMSC
exosomes in periodontitis with possible further development of an innovative and less
invasive regeneration therapy. Current periodontal therapies focus mostly on the
debridement of bacterial pathogens. However, the chronic inflammatory response in the
hosts is correlated with the susceptibility and severity of the disease. Therefore, safe,
effective, and efficient therapies to control the excessive inflammatory response can be
the key of successful treatment for periodontitis. Our previous studies suggested the
regenerative effects of hBMSC exosomes in calvarial defects. It would be exciting if
exosome therapy can also be applied to periodontal regeneration and provide a better
alternative treatment modality which is more time and cost effective and efficacious. Our
study may lead to novel preventive and therapeutic strategies which would benefit
patients with periodontal disease globally.
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CHAPTER 3: METHODS

3.1.

SPECIFIC AIM 1: TO DETERMINE IF hBMSC EXOSOMES WOULD PREVENT

PERIODONTAL INFLAMMATION AND ALVEOLAR BONE LOSS IN LIGATIONINDUCED PERIODONTITIS

Studies in Aim 1 sought to determine if hBMSC exosomes would prevent
periodontal inflammation and alveolar bone loss in ligation induced periodontitis model
in rats. hBMSC exosomes are known to be proliferative, chemotactic, anti-inflammatory,
and anti-resorptive from in vitro studies. With our ultimate goal to develop a more
effective clinical therapy for periodontal defects, in vivo studies are the reasonable next
step in progression. We first tested if hBMSC exosomes can exert immunomodulatory
function to prevent periodontal inflammation and alveolar bone loss.

20 Male Sprague-Dawley rats (250-300g) were divided into 2 groups: exosome
treatment and control. The rats were anesthetized with isoflurane. Buprenorphine was
administered pre-surgically for pain management. 3-0 silk sutures were placed into the
gingival sulci around the maxillary left second molar (Figure 4). The sutures were left in
place for three weeks to induce experimental periodontitis. Both groups received weekly
injections concurrently with suture placement. Injections were administered locally at
two palatal gingival tissue sites: interdental papillae between 1st and 2nd molars and
2nd and 3rd molars of the left maxilla. Exosome treatment group received 1.6 µg
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Figure 4: (A) Rats were laid down on the back and both upper and lower jaws were
immobilized by fixing a string. (B) 3-0 suture was placed around the maxillary left
second molar. Suture was first passed through interdentium between second and
third molar apically. Same suture was passed through another interdentium between
first and second molar apically. Suture was looped around the neck of the second
molar and tied firmly using a triple-knot. Excess suture was cut. Source: A) (Muraoka
et al., 2018), B) (Abe & Hajishengallis, 2013)

exosomes on weekly injection day: 2.5 µL of exosomes per injection site with 0.33
µg/µL concentration. Exosomes were harvested from hBMSC culture media through
sequential ultracentrifugation and quantified by measuring the total protein content
through BCA assay. Same volume of saline was injected to the control group. After 3
weeks, rats were euthanized with CO2 and the maxillae were harvested and fixed in
10% formalin for further analysis (Figure 5).
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Figure 5: First injection was done on the same day of ligature placement (red).
Injections (green) were given three times weekly. After 3 weeks, rats were euthanized
with CO2.

3.1.1. AIM 1.1: TO DETERMINE THE EFFECT OF hBMSC EXOSOMES ON
ALVEOLAR BONE LOSS VIA MICRO-CT ANALYSIS

The fixed left and right maxillae were scanned by a micro-CT machine, Bruker
SkyScan 1173. Obtained images were reconstructed using NRecon Reconstruction
software. Reconstructed images were opened in DATAVIEWER software to align each
sample with standard parameters shown in Figure 6. Transverse plane of each aligned
samples was saved for volumetric analysis. Sagittal plane of each aligned samples was
saved for alveolar bone level analysis.

For volumetric analysis, the transverse plane images of samples were opened in
CTAn software. Region of interest (ROI) was established in 121 transverse plane layers
19

Figure 6: Three planes of the sample can be viewed in DATAVIEWER software. (A)
First, the mesial end of first molar and the distal end of the third molar were aligned
along with the vertical blue line from the transverse plane at the cementoenamel
junction (CEJ) of the second molar. (B) Second, the buccal CEJ and the palatal CEJ of
the second molar were aligned along with the horizontal red line from the coronal
plane. (C) Third, the mesial CEJ and the distal CEJ of the second molar were aligned
along with the horizontal red line from the sagittal plane.

starting from the top layer which is the CEJ of the second molar. Two ROIs, one was
the area between the first molar and second molar and the other was the area between
the second molar and third molar, were traced by hand using computer mouse in all 121
layers as shown in Figure 7. Once the ROI drawing is complete, bone volume was
quantified with setting threshold within the software. Threshold was found to be the
lowest acceptable pixel brightness of the bone area. Values above are counted as solid
20

Figure 7: (A) Bone volume was measured in two different area, zone 1 and zone 2.
Zone 1 is the area between the first molar and the second molar. Zone 2 is the area
between the second molar and the third molar. ROI was drawn in the transverse
plane with the straight tangent line from four roots in each zone as the connecting
boundaries of the ROI. (B) The process of drawing the ROI of zone 1 was repeated
approximately every 5 layers. (C) The process of drawing the ROI of zone 2 was
repeated approximately every 5 layers.
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bone. Quantitative analysis provided the value of tissue volume (TV), bone volume (BV),
and a ratio of the two (BV/TV) that represents the percentage of total bone within the
ROI.

Figure 8: CEJ of the first molar (M1) and the second molar (M2) were connected with
the straight line. From the midpoint of this line, a perpendicular straight line was
drawn to alveolar bone crest (ABC). This perpendicular line was measured for the
alveolar bone level analysis. Same measurement was done between the M2 and the
third molar (M3).

For alveolar bone level analysis, the sagittal plane images of samples were
opened in CTAn software. Among those sagittal plane images, one or two sagittal plane
images that the crowns of the first molar, second molar, and third molar were contacted
to each other were selected. These images were opened in ImageJ software. The CEJ
midpoints between the first molar and second molar and also between the second molar
and third molar were located using line tools. From the midpoint, a perpendicular line
22

was drawn to the alveolar bone crest (ABC) as shown in Figure 8. This perpendicular
line was measured to represent the linear bone loss measurement for alveolar bone
level analysis.

3.1.2. AIM 1.2: TO PERFORM HISTOLOGICAL ANALYSIS OF PERIODONTAL
TISSUE FROM THE PREVENTATIVE MODEL

After micro-CT analysis, maxillae samples were decalcified in a 14% EDTA
solution that was pH balanced to 7.2-7.4 with 10N NaOH. The samples were placed in
the solution with a stir bar to ensure constant movement and placed in a cold room for
approximately 16 days. Once the samples became soft, they were rinsed four times
with H2O and the samples were temporarily placed back into formalin until ready for
embedding and sectioning. With help from the CMMC (Cancer Mouse Models Core,
Massey Cancer Center, Richmond, VA), the samples were embedded in paraffin blocks
and sectioned in the sagittal plane from the palatal side so that the roots of the molars
are visible. The sections were placed on slides and stained with Hematoxylin and Eosin
(H&E). The H&E stain helped visualize tissue morphology and allowed for qualitative
analysis of the samples. Images were captured using Phenochart, a slide visualizer
supplied by PerkinElmer.

3.1.3. AIM 1.3: TO PERFORM A HISTOMORPHOMETRIC ANALYSIS OF INFILTRATED
LYMPHOCYTES IN GINGIVAL SUBEPITHELIAL TISSUE TO DETERMINE THE EFFECT OF
EXOSOME ON PERIODONTAL INFLAMMATION
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Figure 9: (A) 20x resolution images of the periodontal tissue between M1 and M2
were changed into grayscale image. Threshold was set at the nucleus of epithelial
layer. Cells which had higher intensity nucleus than the epithelial layer were shown
in blue. (B) From the origianl 20x resolution images, 50μm depth of subepithelial
tisue area, ROI, were drawn in yellow line. (C) The longest diameter of nucleus which
is above threshold within ROI was measured. Another diameter which is the
perpendicular to the first diameter was also measured. If the ratio of those two
diameters were samller than 1 :1.5, the cell was counted as the infiltrated
lymphocytes.
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After obtained the histology images of samples, infiltrated lymphocytes in gingival
subepithelial tissue were quantified. Images of the periodontal tissue between the first
molar and the second molar with 20x magnification were captured from the Phenochart
software. The images were opened in ImageJ software and the infiltrated lymphocytes
were counted based on the criteria as shown in Figure 9. The first criterion was the cells
should have a higher nuclear staining than that of gingival epithelial cells. The second
criterion was that the cells should have smaller nucleus than the epithelial cell nucleus.
The third criterion was that the ratio of two perpendicular diameters of nucleus than 1.5.
Cells matched these criteria within the ROI, which includes a subepithelial area 50μm
from the basal cell layer, were counted as the infiltrated lymphocytes.

3.2.

SPECIFIC AIM 2: TO DETERMINE IF hBMSC EXOSOMES WOULD

PROMOTE PERIODONTAL REGENERATION IN LIGATION-INDUCED
PERIODONTITIS

Studies in Aim 2 sought to determine if hBMSC exosomes would promote
healing in the ligation induced periodontitis. This regenerative model, an extension of
the preventive study, simulates the clinical situation when patients come to the clinics
with existing periodontitis. The hypothesis was that the hBMSC exosomes have
osteogenic potential and promote periodontal regeneration.

52 Male Sprague-Dawley rats (250-300g) were divided into 5 groups: baseline (8
rats), 3-week exosome treatment (11 rats), 3-week control (11 rats), 6-week exosome
treatment (11 rats), and 6-week control (11 rats). The rats were anesthetized with
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Figure 10: Ligature was placed for 3 weeks on the left second molar. Ligature was
removed after 3 weeks and baseline group was sacrificed at this time point. Other
groups received injection at the time of ligature removal. 3 week groups are
sacrificed after 3 weeks of injections. 6 week groups are sacrificed after 6 weeks of
injections.

isoflurane. Buprenorphine was administered pre-surgically for pain management. 3-0
silk sutures were placed into the gingival sulci around the maxillary left second molar as
shown in Figure 4. The sutures were left in place for three weeks to induce experimental
periodontitis. After 3 weeks, rats in the baseline group were euthanized with CO 2 and
the maxillae were harvested and fixed in 10% formalin for further analysis. For all other
groups, sutures were removed and the first injections were given at the same time.
Injections were administered locally at two palatal gingival tissue sites: interdental
papillae between 1st and 2nd molars and between 2nd and 3rd molars of the left
maxilla. Exosome treatment group received a total of 1.7 µg exosomes on weekly
injection day: 2.5 µL of exosomes per injection site with 0.35 µg/µL concentration.
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Exosomes were harvested from hBMSC culture media through sequential
ultracentrifugation and quantified by measuring the total protein content through BCA
assay. Same volume of saline was injected to the control group. 3 weeks after the first
injection, rats from both 3-week exosome treatment and 3-week control groups were
euthanized with CO2 and the maxillae were harvested and fixed in 10% formalin for
further analysis. 6 weeks after the first injection, rats from the 6-week exosome
treatment and 6-week control groups were euthanized with CO2 and the maxillae were
harvested and fixed in 10% formalin for further analysis.

3.2.1. AIM 2.1: TO PERFORM A MICRO-CT ANALYSIS OF BONE VOLUME AND
ALVEOLAR BONE LEVEL TO DETERMINE THE EFFECT OF hBMSC EXOSOMES
ON PERIODONTAL BONE REGENERATION

Both left and right maxillae were scanned using a micro-CT machine, Bruker
SkyScan 1173. Obtained images were reconstructed using NRecon Reconstruction
software. Reconstructed images were opened in DATAVIEWER software to align each
sample with standard parameters shown in Figure 6. Transverse plane of each aligned
samples was saved for volumetric analysis. Sagittal plane of each aligned samples was
saved for alveolar bone level analysis.

For volumetric analysis, the transverse plane images of samples were opened in
CTAn software. Region of interest (ROI) was established in 121 transverse plane layers
starting from the top layer which was the CEJ of second molar. ROI was the area
between 8 roots of the molars: two distal roots of the first molar, four roots of the second
molar, and two mesial roots of the third molar. ROI was traced by hand using computer
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mouse in all 121 layers as shown in Figure 11. Once the ROI drawing was complete,
bone volume was quantified with setting threshold within the software. Threshold was
found to be the lowest acceptable pixel brightness of the bone area. Values above were
counted as solid bone. Quantitative analysis provided the value of tissue volume (TV),
bone volume (BV), and a ratio of the two (BV/TV) that represents the percentage of total
bone within the ROI.

Figure 11: (A) Bone volume is measured in the area between 8 roots; 2 distal roots of
M1, 4 roots of M2, and 2 mesial roots of M3. ROI was drawn in the transverse plane
with the straight tangent line from each root as the connecting boundaries of the
ROI. The process of drawing the ROI was repeated approximately every 5 layers.

For alveolar bone level analysis, the sagittal plane images of samples were
opened in CTAn software. Among those sagittal plane images, one sagittal plane image
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of the midpoint of the second molar was selected. Then, 5 images of every 10 th sagittal
plane image toward both buccal and palatal side from the selected midpoint image were
selected as well. Total 11 sagittal plane images were selected from each sample. The
distance between the CEJ of M2 and the ABC in all 11 images were measured in Image
J software to represent the linear bone loss (Figure 12).

M3

M2

M1

Figure 12: Horizontal line was drawn at the mesial CEJ of the second molar (M2).
From the horizontal line, a perpendicular straight line was drawn to alveolar bone
crest (ABC) between the first molar (M1) and M2. This perpendicular line was
measured for the alveolar bone level analysis. Same measurement was done from
the distal CEJ of M2 and the alveolar crest between the M2 and the third molar (M3).

3.2.2 AIM 2.2: TO DETERMINE THE GENE EXPRESSION PROFILES OF
PERIODONTAL TISSUES DURING INFLAMMATION RESOLUTION AND TISSUE
REGENERATION
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Figure 13: Periodontal Tissue was collected for the gene expression profile
analysis. Red triangles show where the periodontal tissue was collected from;
between M1 and M2, and M2 and M3. Collected samples were placed in 10%
formalin until RNA is extracted.

Periodontal tissues between the first and second molar, and the second and third
molar were collected with B12 surgical scalpel blade (Figure 13) from the baseline
group (4), 3-week exosome treatment (5), 3-week control (5), 6-week exosome
treatment (5) and 6-week control (5). RNA from the periodontal tissue sample was
extracted with Quick-RNATM FFPE kit (Zymo Research). The tissue samples were
digested overnight with twice amount of Proteinase K as suggested from the manual at
55°C. After multiple RNA isolation steps following the manual, RNA was eluted in 15μl
DNase/RNase-Free Water. Concentration of the RNA was measured with NanoDrop TM
One/OneC Microvolume UV-Vis Spectrophotometer (Thermo Scientific).
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High Capacity cDNA Reverse Transcription Kit (Applied Biosystems) was used to
generate cDNA from the extracted RNA. The volume contained ~200ng of RNA of each
sample was calculated. 2.9 μl of RT master mix was prepared on ice by adding, 1.0 μl
of 10X RT Buffer, 0.4 μl of 25X dNTP Mix (100mM), 1 μl of 10X RT Random Primers,
and 0.5 μl of MultiScribe TM Reverse Transcriptase. Calculated volume of the RNA
samples were added along with the RT master mix. If the RNA sample volume needed
was larger than 7.1 μl which was the maximum amount allowed, only 7.1 μl of the RNA
sample was added. Total amount all together should be 10 μl. If the total amount was
smaller than 10 μl, Nuclease-free water was added to make the total amount 10 μl.
Reverse Transcription (RT) reaction was performed at 25°C for 10 minutes, 37°C for
120 minutes, and 85°C for 5 minutes. cDNA were stored at -20°C.

Target-specific preamplification was performed on the cDNA generated from the
extracted RNA. 5 μl of cDNA was preamplified in a volume of 30 μl containing 1x
PerfeCTa® SYBR® Green FastMix® (Quantabio) and 34 primer pairs (Supplementary
Table 1), 40nM of each primer. Preamplification was performed at 95°C for 3 minutes
followed by 20 cycles of amplification at 95°C for 20 seconds, 60°C for 3 minutes, and
72°C for 20 seconds and a final additional incubation at 72°C for 10 minutes.
Preamplified cDNA samples were stored at -20°C. Preamplified cDNA samples were
diluted 1:10 with water before performing the Quantitative real-time PCR (qPCR).

qPCR was performed in the QuantStudio TM 3 Real-Time PCR System (Applied
Biosystems) using 10 μl reactions containing 5 μl of 1x PerfeCTa® SYBR® Green
FastMix® (Quantabio), 400nM of each primer and 2 μl preamplified and diluted cDNA.
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The same primers were used in the target specific preamplification reaction. qPCR was
performed at 50°C for 2 minutes and 95°C for 10 minutes followed by 40 cycles of
amplification at 95°C for 15 seconds and 60°C for 1 minute, followed by a melting curve
ranging from 60°C to 95°C, 2s per 0.3°C increment. The PCR products were used to
run gel electrophoresis in order to validate the primer specificity. 2-ΔΔCt method was
used to calculate relative changes in gene expression. For each animal, the result from
left side was normalized to that from the right side and the fold change was presented.

3.3 STATISTICAL ANALYSIS

All the calculation was done in Excel spreadsheet. The data were analyzed using
unpaired t-test and one-way analysis of variance (ANOVA), followed by Turkey multiplecomparison tests. P-values less than 0.05 were considered statistical significance.
Graphs for each data were prepared using Graph Pad Prism 7.02 (Graph Pad Software,
CA, USA).

32

CHAPTER 4: RESULTS

4.1.

SPECIFIC AIM 1: TO DETERMINE IF hBMSC EXOSOMES WOULD PREVENT

PERIODONTAL INFLAMMATION AND ALVEOLAR BONE LOSS IN LIGATIONINDUCED PERIODONTITIS

Maxillae samples were analyzed by standardized micro-CT protocols and
statistical regression. Tissue morphologies were confirmed by histological analysis.
Infiltrated lymphocytes in the subepithelial tissue were quantified by histomorphometric
analysis.

4.1.1. AIM 1.1: TO DETERMINE THE EFFECT OF hBMSC EXOSOMES ON
ALVEOLAR BONE LOSS VIA MICRO-CT ANALYSIS

In the preventative study, periodontitis was induced on the left maxilla and the
right maxilla remained healthy. The alveolar bone loss analysis was normalized to the
healthy side of the same animal. Bone volume (BV) was divided by the tissue volume
(TV) to calculate the percentage of the bone volume in the ROI (BV/TV). BV/TV was
then normalized to the healthy side BV/TV. The normalized BV/TV in the exosome
treatment group (0.68, p<0.05) was significantly higher than the control group that was
0.56, showing significantly less bone loss in the exosome treatment group (Figure 14).
Alveolar bone level (ABL) was measured by the distance from the CEJ to the ABC in
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Figure 14: The volumetric measurements of the exosome treatment group were
significantly larger than the control group in both the disease side data and the
normalized data. Alveolar bone loss was significantly reduced in the exosome
treatment group.

the interproximal space between molars (Figure 8). If the distance is longer, the ABL is
lower. In opposite, if the distance is shorter, the ABL is higher which means less bone
loss (Figure 15). ABL was only measured in the interproximal space because it was
where the most bone loss occurred due to ligature placement as shown in Figure 16.
The linear distance measurement of the disease side was also normalized to the
healthy side. The normalized linear measurement in the exosome treatment is smaller
than the control group (1.34 vs. 1.67, p=0.06), also indicating less bone loss in the
exosome treatment group (Figure 17).
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Figure 15: ABL is higher when the linear distance measurement from CEJ to ABC
shown in blue line is smaller. Higher ABL means less alveolar bone loss. ABL is
lower when the linear distance measurement from CEJ to ABC shown in yellow line
is larger. Lower ABL means more alveolar bone loss.

Figure 16: (B) Linear distance measurements from CEJ to ABC were done in 9
different locations. (A) Results showed that the most bone loss happens in the
interproximal space, Z1 and Z2. The green arrow showed the data points at M2.
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Figure 17: The linear distance measurements of the exosome treatment group were
significantly smaller than the control group in both disease side data and the
normalized data, denoting significantly higher ABL. Alveolar bone loss was
significantly reduced in the exosome treatment group.

4.1.2. AIM 1.2: TO PERFORM HISTOLOGICAL ANALYSIS OF PERIODONTAL TISSUE
FROM THE PREVENTATIVE MODEL

A histological analysis was used to provide insight of the effects exosomes may
have on tissue morphology. H&E stained histology images of the control group exhibited
prominent epithelial hyperplasia. In contrast, the exosome treatment group showed less
increased epithelial cell proliferation (Figure18). Also, there was more severe apical
migration of junctional epithelium observed in the control group than the exosome
treatment group (Figure19).
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Figure 18: H&E stained histology sections showed that there were more increased
epithelial cell proliferation in the control group than the exosome treatment group.
The epithelial layer of control group is marked with yellow circle. The epithelial layer
of exosome treatment group is marked with green circle.
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Figure 19: H&E stained histology sections showed that there were more severe
apical migration of junctional epithelium (JE) in the control group than the exosome
treatment group. CEJ is marked with black line. Apical migration of JE of the control
group is marked with yellow arrow. Apical migration of JE of the exosome group is
marked with green arrow.
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4.1.3. AIM 1.3: TO PERFORM A HISTOMORPHOMETRIC ANALYSIS OF INFILTRATED
LYMPHOCYTES IN GINGIVAL SUBEPITHELIAL TISSUE TO DETERMINE THE EFFECT OF
EXOSOME ON PERIODONTAL INFLAMMATION

Infiltrated lymphocytes in the subepithelial tissue were quantified from the 20x H&E
stained histology images. Lymphocytes are mostly small in size. Their nucleus appears as
dense purple and monochromatic round shape. These characteristics made it clear to identify
infiltrated lymphocytes in subepithelial tissue from the H&E stained histology images (Figure 20).
In average, there are 2135 infiltrated lymphocytes/mm2 in the control group. Significantly less
amount of the infiltrated lymphocytes was found in the exosome group, shown in Figure 21
(1686, p<0.05).

Figure 20: Red arrow indicates infiltrated lymphocyte. Lymphocytes have round dark
nucleus surrounded by a narrow rim of cytoplasm. There are clear distinction
between cytoplasm and nucleus in the color intensity. Most of the lymphocytes are
small in size.
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Figure 21: There are significantly less infiltrated lymphocytes in the subepithelial
tissue from the exosome treatment group than the control group (p<0.05).

4.2.

SPECIFIC AIM 2: TO DETERMINE IF hBMSC EXOSOMES WOULD

PROMOTE PERIODONTAL REGENERATION IN LIGATION INDUCED
PERIODONTITIS

Maxillae samples were analyzed by standardized micro-CT protocols and statistical
regression. Macrophage related gene expression was analyzed in the periodontal tissue to
create a gene expression profile during bone regeneration.

40

4.2.1. AIM 2.1: TO PERFORM A MICRO-CT ANALYSIS OF BONE VOLUME AND
ALVEOLAR BONE LEVEL TO DETERMINE THE EFFECT OF hBMSC EXOSOMES
ON PERIODONTAL BONE REGENERATION

A)

B)

Figure 22: (A) Baseline group has significantly less normalized BV/TV than other
groups: 3-week exosome treatment group, 6-week exosome treatment group, and 6week control group. (B) Baseline group has significantly longer distance from CEJ to
ABC, meaning lower alveolar bone level (ABL). P-values were indicated on the
graph.
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In the regenerative study, periodontitis was induced on the left maxilla and the right
maxilla remained healthy. The alveolar bone loss analysis was normalized to the healthy side of
the same animal. For bone volume measurement, the differences between the exosome
treatment group and the control group at both 3-week and 6-week didn’t reach statistical
significance. Similarly there was no significant difference between the exosome group and the
control group at both 3-week and 6-week in the alveolar bone level analysis. However, the
baseline group had significantly less bone volume than the 3-week exosome treatment group
(p<0.05) and both 6-week groups (p<0.001). Also, there was significantly lower alveolar bone
level (after normalization to the right side) at the baseline compared to all other four groups
showing the ligature placement successfully induced periodontitis. The increasing bone volume
and alveolar bone level showed a natural healing progression with time. (Figure 22).

4.2.2 AIM 2.2: TO DETERMINE THE GENE EXPRESSION PROFILES OF
PERIODONTAL TISSUES DURING INFLAMMATION RESOLUTION AND TISSUE
REGENERATION

Periodontal tissues from the regenerative model were collected. cDNA was
generated from the extracted RNA from the collected periodontal tissues. RT-qPCR was
done to determine the expression of genes related to inflammation activation and
resolution. A panel of 34 genes was selected and primers targeting these genes were
designed (supplementary table 1). The transition of macrophages from M1 phase to M2
phase is a keystone step in the healing process. Due to time limitation, the expression
of one gene from each M1 and M2 gene pool were analyzed. Each gene (TNFα and
TGM2) was selected after the validation of the specificity and efficiency of primers by
gel electrophoresis (Figure 23) and RT-qPCR. Both TNFα and TGM2 gene expression
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didn’t show any significant trend during the bone regeneration process (Figure 24) due
to the small number of sample size (n=4 or 5).

Figure 23: (A) (B) (C) Primer specificity
for all 34 primers for the gene of interest
was validated with gel elctrophoresis.
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A)

B)

C)

D)

-ΔΔCt

Figure 24: 2
method was used to calculate relative changes in gene expression.
(A) TNFα expression was normalized to β-Actin, (B) TGM2 expression was
normalized to β-Actin, (C) TNFα expression was normalized to GAPDH, (D) TGM2
expression was normalized to GAPDH. (A)(B)(C)(D) Disease side was normalized to
the healthy side.
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CHAPTER 5: DISCUSSION

In the past decades, exosome therapy has received a lot of attention due to its
ability to regulate cell and tissue function in the regeneration process. Studies have
shown that exosomes are osteogenic and anti-resorptive in bone disease (88-90).
Periodontal disease is caused by the accumulation of bacteria which activates the
inflammatory response. The continued presence of bacteria results in the destruction of
periodontal tissue including alveolar bone (91). In this study, we hypothesized that
hBMSC exosomes prevent alveolar bone loss and have regenerative potential in
diseased periodontium.
In the preventative study, we found that hBMSC exosomes reduced periodontal
inflammation and alveolar bone loss. We were able to set up a standard Micro-CT
protocol for rat maxillae samples, and therefore reliable and reproducible data were
generated. Bone volume and alveolar bone level analysis showed the reduction of the
alveolar bone loss after the exosome treatment. This suggests that the exosomes have
a preventative effect on the alveolar bone, which is similar to what was shown in other
degenerative bone diseases (88). In healthy periodontium, junctional epithelium is
attached onto enamel and protects the tooth surface. With the invasion of bacterial
pathogenic components, junctional epithelium is detached from the enamel and
migrates down to the root, which creates pockets (92). Also, the epithelial tissue
interacts with bacterial pathogens through TLRs producing cytokines and proteinases
which lead to epithelial proliferation and migration into the inflamed area (93, 94).
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Imbalanced immune response to the consistent bacterial insults leads to the destruction
of periodontal tissue, which is associated with the infiltration of lymphocytes into the
connective tissue (95). We observed lesser extent of epithelial cell proliferation and
apical migration and reduced amount of infiltrated lymphocytes in the subepithelial
tissue after the exosome treatment. Overall, this preventative study demonstrated the
possibility of exosomes to be a protective agent for periodontal disease with the ability
of regulating inflammatory response.
Histomorphometric analysis was used instead of immunohistochemistry to
quantify the infiltrated lymphocytes in this study because we encountered technical
difficulties finding antibodies for lymphocytes. We can continue to try different antibodies
to detect and visualize the lymphocytes in the future study to confirm the findings in our
current study.
In the regenerative model, our data didn’t support that hBMSC exosomes promote
the alveolar bone regeneration. Many factors may be associated with the results. For
example, the dosage of exosomes should be further explored. We observed the efficacy
of the exosomes in the preventive study. The main difference between the two models
is the timepoint of the injection of hBMSC exosomes. Administering of hBMSC
exosomes starting at the healthy stage or the early stage of immune response may
have been enough to suppress the inflammatory response and subsequently prevent
alveolar bone destruction, however, higher exosome concentration may be needed to
enhance the tissue repair in the presence of severe periodontitis. The fact that the
regenerative effect of exosomes is dose dependent has also been shown in other bone
diseases (96-98). Also, different methods to deliver the exosomes can be tested in the
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future. In this study, we used subgingival injection because it is easy and less invasive.
However, the amount of exosomes that can be delivered through this method is limited
due to the small injection volume (~2 μl/site). Excessive liquid volume will lead to tissue
necrosis. It is also not clear how long the exosomes can stay at the disease site after
the injection. Other studies also indicated the importance of delivery strategy. Chew et
al. demonstrated that exosome loaded in collagen sponge promoted regeneration
potential (98).
The self-regeneration of periodontium was appreciated in our regenerative model,
which was shown by the increased BV/TV values at 6-week comparing to baseline. This
phenomenon has also been documented in literature (99, 100). To explore the
important genes that are involved in the inflammation resolution and tissue regeneration
process, we designed a panel of primers targeting genes involved in the transition of
macrophages (M1-M2), key enzymes in the metabolism of lipidic inflammation
resolution products, cytokines and growth factors. Periodontal tissue was collected from
the formalin fixed maxillae sample to extract RNA. RNA integrity was assessed prior to
further process. In order to obtain reliable data from the downstream research process,
RIN number usually should be above 7. Our extracted RNA showed RIN numbers
between 2 and 3, indicating that formalin fixation broke down RNA molecules and
modified RNA. The poor RNA quality might contribute to the large variance that we saw
in the PCR results. Other studies suggested that using formalin free fixative, such as
PAXgene Tissue System (101) and cryopreservation (102), can improve the RNA
quality to enhance the comparability and reliability of RT-PCR experiments. Even
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though our preliminary gene expression results didn’t lead us to any conclusion yet,
we’ve demonstrated the feasibility of our strategy for future studies.
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CHAPTER 6: CONCLUSION

Current traditional periodontal disease treatments focus mainly on mechanical
debridement. Adjunctive treatments such as systemic antibiotics are associated with
serious complications and antibiotic resistance. It is important to direct route of our
journey in developing future preferential therapy to harness the host immune system
modulation strategy since the destruction of periodontal tissues was done directly by
host immune response. Cell-based treatments using MSCs are thought to be an
alternative novel therapy due to its pleiotropic effects. Problem of scarcity and possible
oncogenic potential with utilizing MSCs can be solved with hBMSC exosomes as they
convey the regenerative factors including specific nucleic acids and proteins from
parental cells.

Our study evaluated the protective and regenerative potential of hBMSC
exosomes in the application of periodontal regeneration in ligature-induced
experimental periodontitis in rats. hBMSC exosomes significantly reduced periodontal
inflammation and alveolar bone loss in an experimental periodontitis model. When
applied as a therapeutic agent, hBMSC exosomes did not show statistically superior
effects compared to control. Interestingly, natural inflammation resolution and tissue
regeneration was observed in the study, which may be worthwhile for further research
to understand the underlying mechanism. Overall, this study suggested that hBMSC
exosome may be a key agent as a host modulation therapy for periodontitis.
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SUPPLEMENTARY DATA
Supplementary Table 1. Primers used for RT-qPCR detection in this study
Gene
GAPDH
Actin-b
Hprt1

Forward Primer (5'->3')
AGTGCCAGCCTCGTCTCATA
CGCGAGTACAACCTTCTTGC
TCCTCCTCAGACCGCTTTTC

Reverse Primer (5'->3')
GGTAACCAGGCGTCCGATAC
CGTCATCCATGGCGAACTGG
ATCACTAATCACGACGCTGGG

Product Length
77
70
78

Tm (C)
60
60
60

M1: pro-inflammatory

IL1b
IL6
TNFa
IL23
IL12b
IL12a
IL17a
IL17b
IL17c
IL17d
IL17f

TAGCAGCTTTCGACAGTGAGG
CATTCTGTCTCGAGCCCACC
ATGGGCTCCCTCTCATCAGT
AAAAGTGACGTGCCCCGTAT
GAGGCCCAGCAGCAGAATAA
GCCTGCTTACCACTGGAACT
GGAGAATTCCATCCATGTGCC
CACACAGCCTGCTCTTCCTT
ACTGCCACTGTGATGTGTCT
CCCCACCTCCTAACAAGTCTG
TTCTATTGCGTGACCCGGAG

TCTGGACAGCCCAAGTCAAG
GCTGGAAGTCTCTTGCGGAG
TGGTTTGCTACGACGTGGG
TGCAAACAGAACTGGCTGTTG
GGTGGGTCCGGTTTGATGAT
GCAGGCAGCTCCCTCTTATT
ATGAGTACCGCTGCCTTCAC
GCCCCTTCCTTTTGCCTTTG
AATGGGGGATCTTGGTGGGT
GAGGGCATCCAGACCAGTGTC
GGAGCCCTTCATGCTGGATT

100
91
100
80
77
85
76
84
71
70
87

60
60.5
60
60
59
59
60
60
60
60
60

M2: inflammation resolution

IL10
TGFb1
ARG1
MRC1
IL1ra
IL4
IL13
TGM2
Anxa1
Tnfaip3/A20
ALOX15
ALOX15B
ALOX5
Edil3/Del1
Ptgs2/Cox2

TGCGACGCTGTCATCGATTT
CTGCTGACCCCCACTGATAC
ACAAGACAGGGCTACTTTCAGG
TCAACTCTTGGACTCACGGC
TCCTTCTCATCCTTCTGTTTCGT
AACAAGGAACACCACGGAGA
GATCCACATCTCCCCCTGTG
GTTCCTGAAGGACCGTAGCC
GGAAGACAAGGCAATACAAAGATAC
TGCTACGACACTCGGAACTG
GGTTGGTTGGACAGCATGGA
GACCGTGAAAGACTTGGACCT
GGCGGTCGCGACTCCTAT
CTGTCAGGATTGGCGGATGA
TCCCATGGGTGTGAAAGGAAA

AGACACCTTTGTCTTGGAGCTT
AGCCCTGTATTCCGTCTCCT
TGCCGTGTTCACAGTACGAG
GAACGGAGATGGCGCTTAGA
CCCAGATTCTGAAGGCTTGC
TGTTCTTCAAGCACGGAGGT
GGGAAGTCTTCTGGTCTTGTGT
CATTGCAGTTGACCATGCCG
ACATATTCCTGCTCTTGCTTTTCA
GTACTGAAGTCCACTCCGGG
AATTCTGCTTCCGAGTCCCG
TCAGCTCTGTAAACGCAGACT
GCCTGTATTTGCGCTTCTCG
TCTGATGCAACCTCCACAACA
CTTGGGGATCCGGGATGAAC

96
94
95
83
87
98
78
89
100
93
73
92
85
92
95

60
60
60
59
59
59
59
60
58
59
60
59
60
59
60

Osteoclast Differentiation

Tnfsf11/RANKL
Tnfrsf11b/OPG

GAGCGCAGATGGATCCTAACA
AGAGAAGCACCTAGCACTGG

GTCGAGTCCTGCAAACCTGT
GTCCAAGAACACCAGGAGTG

97
99

60
59

BET

BRD2
BRD3
BRD4

GTGACTCCCCACAAGCTCC
CTAGCGTCTCAGAGTGCCT
CTAGCGTCTCAGAGTGCCT

ATCCTTTTCCCTGGTGCTGC
TCTCAATCTTGTCCCAGGGC
TCTCAATCTTGTCCCAGGGC

83
82
82

60
58
59

Housekeeping Gene
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